Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer

AB. Benson, I. Kiss, J. Bridgewater, FA. Eskens, C. Sasse, S. Vossen, J. Chen, C. Van Sant, HA. Ball, A. Keating, A. Krivoshik,

. 2016 ; 22 (20) : 5058-5067. [pub] 20160711

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18011122

PURPOSE: Tivozanib, a selective inhibitor of VEGFR-1, -2, and -3, plus mFOLFOX6 in an advanced gastrointestinal cancer phase Ib study had encouraging antineoplastic activity and a tolerable safety profile. This randomized, open-label, phase II trial of tivozanib/mFOLFOX6 versus bevacizumab/mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (mCRC) evaluated tivozanib activity versus bevacizumab. EXPERIMENTAL DESIGN: Treatment-naïve patients received mFOLFOX6 every 2 weeks of each 28-day cycle plus either tivozanib orally 1.5 mg once daily for 21 days or bevacizumab intravenously 5 mg/kg every 2 weeks. Investigator-assessed progression-free survival (PFS) was the primary endpoint; some secondary endpoints included safety, overall survival, overall response rate (ORR), duration of response, time to treatment failure, and biomarker subgroup analyses. RESULTS: A prespecified interim futility analysis demonstrated that the futility boundary for superiority of tivozanib/mFOLFOX6 over bevacizumab/mFOLFOX6 for PFS in the intent-to-treat population was crossed; median PFS was 9.4 versus 10.7 months [HR = 1.091; confidence interval (CI), 0.693-1.718; P = 0.706]. Tivozanib/mFOLFOX6 resulted in PFS and ORR comparable with bevacizumab/mFOLFOX6; interim analyses biomarker results revealed no significant PFS association. Post hoc final analyses demonstrated a potential difference in tivozanib-specific PFS in patients with low neuropilin-1 (NRP-1), but not in patients with high NRP-1. Tivozanib/mFOLFOX6 was tolerable and adverse events were comparable with both bevacizumab/mFOLFOX6 and previous tivozanib studies. CONCLUSIONS: The efficacy of tivozanib/mFOLFOX6 was comparable with but not superior to bevacizumab/mFOLFOX6 in patients with previously untreated mCRC. Since data from the prespecified interim analysis did not demonstrate superiority, this resulted in discontinuation of the study. The safety and tolerability profile of tivozanib/mFOLFOX6 was consistent with other tivozanib trials. NRP-1 is a potential predictive biomarker for tivozanib activity, but these results require further validation. Clin Cancer Res; 22(20); 5058-67. ©2016 AACR.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011122
003      
CZ-PrNML
005      
20180416095413.0
007      
ta
008      
180404s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1078-0432.CCR-15-3117 $2 doi
035    __
$a (PubMed)27401244
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Benson, Al B $u Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois. a-benson@northwestern.edu.
245    10
$a BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer / $c AB. Benson, I. Kiss, J. Bridgewater, FA. Eskens, C. Sasse, S. Vossen, J. Chen, C. Van Sant, HA. Ball, A. Keating, A. Krivoshik,
520    9_
$a PURPOSE: Tivozanib, a selective inhibitor of VEGFR-1, -2, and -3, plus mFOLFOX6 in an advanced gastrointestinal cancer phase Ib study had encouraging antineoplastic activity and a tolerable safety profile. This randomized, open-label, phase II trial of tivozanib/mFOLFOX6 versus bevacizumab/mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (mCRC) evaluated tivozanib activity versus bevacizumab. EXPERIMENTAL DESIGN: Treatment-naïve patients received mFOLFOX6 every 2 weeks of each 28-day cycle plus either tivozanib orally 1.5 mg once daily for 21 days or bevacizumab intravenously 5 mg/kg every 2 weeks. Investigator-assessed progression-free survival (PFS) was the primary endpoint; some secondary endpoints included safety, overall survival, overall response rate (ORR), duration of response, time to treatment failure, and biomarker subgroup analyses. RESULTS: A prespecified interim futility analysis demonstrated that the futility boundary for superiority of tivozanib/mFOLFOX6 over bevacizumab/mFOLFOX6 for PFS in the intent-to-treat population was crossed; median PFS was 9.4 versus 10.7 months [HR = 1.091; confidence interval (CI), 0.693-1.718; P = 0.706]. Tivozanib/mFOLFOX6 resulted in PFS and ORR comparable with bevacizumab/mFOLFOX6; interim analyses biomarker results revealed no significant PFS association. Post hoc final analyses demonstrated a potential difference in tivozanib-specific PFS in patients with low neuropilin-1 (NRP-1), but not in patients with high NRP-1. Tivozanib/mFOLFOX6 was tolerable and adverse events were comparable with both bevacizumab/mFOLFOX6 and previous tivozanib studies. CONCLUSIONS: The efficacy of tivozanib/mFOLFOX6 was comparable with but not superior to bevacizumab/mFOLFOX6 in patients with previously untreated mCRC. Since data from the prespecified interim analysis did not demonstrate superiority, this resulted in discontinuation of the study. The safety and tolerability profile of tivozanib/mFOLFOX6 was consistent with other tivozanib trials. NRP-1 is a potential predictive biomarker for tivozanib activity, but these results require further validation. Clin Cancer Res; 22(20); 5058-67. ©2016 AACR.
650    _2
$a inhibitory angiogeneze $x terapeutické užití $7 D020533
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a bevacizumab $x škodlivé účinky $x terapeutické užití $7 D000068258
650    _2
$a nádorové biomarkery $x krev $7 D014408
650    _2
$a kolorektální nádory $x farmakoterapie $x patologie $7 D015179
650    _2
$a progrese nemoci $7 D018450
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluoruracil $x škodlivé účinky $x terapeutické užití $7 D005472
650    _2
$a lidé $7 D006801
650    _2
$a leukovorin $x škodlivé účinky $x terapeutické užití $7 D002955
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neuropilin-1 $x krev $7 D039942
650    _2
$a organoplatinové sloučeniny $x škodlivé účinky $x terapeutické užití $7 D009944
650    _2
$a fenylmočovinové sloučeniny $x škodlivé účinky $x terapeutické užití $7 D010671
650    _2
$a chinoliny $x škodlivé účinky $x terapeutické užití $7 D011804
650    _2
$a receptory vaskulárního endoteliálního růstového faktoru $x antagonisté a inhibitory $7 D040262
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Kiss, Igor $u Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Bridgewater, John $u University College London Cancer Institute, London, United Kingdom.
700    1_
$a Eskens, Ferry A L M $u Eramus MC Cancer Institute, Rotterdam, the Netherlands.
700    1_
$a Sasse, Carolyn $u Astellas Pharma Global Development, Northbrook, Illinois.
700    1_
$a Vossen, Sandra $u Astellas Pharma Global Development, Northbrook, Illinois.
700    1_
$a Chen, Jihong $u Astellas Pharma Global Development, Northbrook, Illinois.
700    1_
$a Van Sant, Chip $u Astellas Pharma Global Development, Northbrook, Illinois.
700    1_
$a Ball, Howard A $u Astellas Pharma Global Development, Northbrook, Illinois.
700    1_
$a Keating, Anne $u Astellas Pharma Global Development, Northbrook, Illinois.
700    1_
$a Krivoshik, Andrew $u Astellas Pharma Global Development, Northbrook, Illinois.
773    0_
$w MED00001121 $t Clinical cancer research an official journal of the American Association for Cancer Research $x 1078-0432 $g Roč. 22, č. 20 (2016), s. 5058-5067
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27401244 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180416095510 $b ABA008
999    __
$a ok $b bmc $g 1288607 $s 1007934
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 22 $c 20 $d 5058-5067 $e 20160711 $i 1078-0432 $m Clinical cancer research $n Clin Cancer Res $x MED00001121
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace